Hybrid HA-Polymer Filler Shows Early Results in Nonsurgical Rhinoplasty
Key Takeaways
- An investigational hybrid filler combining cross-linked hyaluronic acid (HA), polycaprolactone (PCL), and polylactic acid (PLA) microspheres produced short-term aesthetic improvement after nonsurgical rhinoplasty in a 150-patient pilot study.
- At 3 months, 83.3% of participants were rated Improved or Very Improved on the Global Aesthetic Improvement Scale (GAIS), and 86.7% reported satisfaction scores of 4 or 5.
- No serious adverse events were observed during 3 months of follow-up, but the uncontrolled design and short follow-up limit conclusions about comparative efficacy, durability, and long-term safety.
An investigational hybrid dermal filler combining cross-linked hyaluronic acid (HA) with polycaprolactone (PCL) and polylactic acid (PLA) microspheres showed short-term aesthetic improvement and generally mild treatment-emergent adverse events.
Researchers for the uncontrolled study included 150 adults from a single center in the analysis who underwent nonsurgical rhinoplasty and were evaluated through 3 months. Investigators assessed safety and tolerability alongside Global Aesthetic Improvement Scale (GAIS) ratings, patient satisfaction, nasal tip projection, dorsal height, and procedural characteristics.
Nonsurgical Rhinoplasty Outcomes at 3 Months
At month 1, 86.7% of participants received GAIS ratings of Improved or Very Improved vs 83.3% at month 3. Satisfaction scores of 4 or 5 were reported by 90.0% and 86.7% at months 1 and 3, respectively. Objective measurements also showed early changes in nasal contour. Tip projection increased by more than 1.5 mm in 70.0% of participants; 63.3% experienced an increase in dorsal height of more than 2.0 mm.
“The investigational formulation demonstrated favorable short-term tolerability and early aesthetic improvement in an uncontrolled pilot setting,” the authors wrote. “These findings do not establish comparative effectiveness, long-term durability, tissue integration, or long-term biocompatibility. Controlled studies with extended follow-up are required.”
Source
Chen H, et al. Clinical Cosmetic Investigative Dermatology. 2026. Doi:10.2147/CCID.S635669